CAMBRIDGE, Mass., July 16 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) today announced that James L. Vincent is retiring
as Chairman of the Board and as a Director of Biogen. The Board has elected
James C. Mullen as Chairman. He will continue in his role as Chief Executive
Officer.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
The Board stated, "We are grateful for the many significant contributions
made by Jim Vincent during his 16 years of leadership at Biogen. We are
confident that Jim Mullen's leadership skills and breadth of experience will
drive Biogen to the next level as a multi-product, global biotechnology
company."
Mr. Mullen's election as Chairman completes a long-standing, planned
transition under which Mr. Mullen succeeded Mr. Vincent as Chief Executive
Officer in June 2000. In connection with this transition, Mr. Vincent will
receive severance and other benefits consistent with his 1996 employment
agreement.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and European sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, (Please see full prescribing information at
http://www.avonex.com.), and from the worldwide sales by licensees of a number
of products, including alpha interferon and hepatitis B vaccines and
diagnostic products. Biogen's research and development activities are focused
on novel products to treat inflammatory and autoimmune diseases, neurological
diseases, cancer, fibrosis and congestive heart failure. The Company
maintains active clinical research programs in protein therapeutics, small
molecules, genomics and gene therapy. For copies of press releases and
additional information about the Company, please consult Biogen's homepage on
the World Wide Web at http://www.biogen.com.
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com.
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/101550.html
CONTACT:
Media Contact: Tim Hunt, Director, Public
Affairs, +1-617-679-4996, or Investment Community Contact:
Elizabeth Woo, Director, Investor Relations +1-617-679-2822, both
of Biogen, Inc.
|
